Fresenius raises 2026 outlook after Q2 profit beat

Fresenius SE & Co. KGaA

05/08/2026 06:41

Aug 5 (Reuters) - German healthcare group Fresenius FREG.DE raised its 2026 outlook on Tuesday after it beat market expectations for second-quarter operating earnings, led by a better-than-expected performance at its generic hospital medications division Kabi.
Since taking the helm in 2022, CEO Michael Sen has been revamping Fresenius' organization to reduce costs and liabilities, which included ceding control of dialysis unit Fresenius Medical Care FMEG.DE in 2023 and centring the strategy around Fresenius Kabi.
Fresenius expects its adjusted operating earnings per share to grow by 10-15% in 2026, having previously guided for 5-10%.
Q2 adjusted earnings before interest, taxes and special effects were €719 million ($829 million), above a Vara consensus of €693.1 million.
"Fresenius today has a fundamentally different earnings, returns, and cash-generation profile than it did in 2022," Sen said.
($1 = 0.8672 euros)

(Reporting by Tristan Veyet in Gdansk, editing by Milla Nissi-Prussak)
((tristan.veyet@thomsonreuters.com ))